Hemophilia A Models

Autoimmune Disease Models
Autoimmune Nephropathy ModelsAsthma ModelsSystemic Lupus Erythematosus (SLE) ModelsSjögren's Syndrome ModelsAutoimmune Dermatoses Models Neuroimmune Disease ModelsInflammatory Bowel Disease ModelsRheumatoid Arthritis ModelsImmune Reconstitution Autoimmune Disease Models
Metabolic Disease Mouse Models
Obesity ModelsDiabetes ModelsMASH ModelsOsteoporosis ModelsHyperuricemia Models
Wild Mouse 750
Wild Mouse 750
Rare Disease Mouse Models
Autosomal Dominant Polycystic Kidney Disease (ADPKD)Progressive Muscular Dystrophy ModelsHemophilia A Models
Neurological Disease Mouse Models
Alzheimer's Disease (AD) ModelsHumanized Alzheimer's Disease (AD) ModelsParkinson's Disease (PD) ModelsHuntington's Disease (HD) ModelsAmyotrophic Lateral Sclerosis (ALS) ModelsTransthyretin Amyloidosis (ATTR) ModelsPain Mouse ModelsDuchenne Muscular Dystrophy (DMD) Models
Oncology Mouse Models
Human Xenograft ModelsDrug ResistanceT-Cell EngagersHumanized Immune Checkpoint ModelsHumanized Immune System ModelsSpontaneous Tumor Models
Cardiovascular Disease Mouse Models
Heart Failure ModelsHypertension ModelsAtherosclerosis ModelsAdvanced Cardiovascular and Metabolic Complication ModelsHyperlipidemia ModelsHypertropic Cardiomyopathy ModelsStroke ModelsThrombosis Models
Humanized Immune System Models
huPBMC-NCGhuHSC-NCG-XhuHSC-NCG-hIL15huHSC-NCG
Organs or Tissue Humanized Mouse Models
Wild Mouse 765
Wild Mouse 765

Hemophilia is a coagulation disorder caused by mutations in specific genes encoding clotting factors. There are two major categories of hemophilia: hemophilia A and B. 80 to 85% of patients with hemophilia are affected by hemophilia A or B. Hemophilia is characterized by either spontaneous or non-spontaneous bleeding, including uncontrollable bleeding during trauma or surgery and irreversible joint injury resulting from frequent bleeding in the joint cavity. Hemophilia A (HA) is a bleeding disorder caused by the absence of clotting factor VIII (FVIII), which is primarily produced and secreted by the liver into the bloodstream. FVIII participates in the endogenous clotting pathway, activating downstream clotting factors and prothrombin via a series of cascades with amplification effects, which activates thrombinogen, ultimately producing a hemostatic plug to stop bleeding. Its coding gene, FVIII, is located on the X chromosome, and different mutations, including point mutations, missense mutations, translocations, and insertions can lead to insufficient synthesis or malfunction of FVIII and the development of hemophilia.

GemPharmatech has developed a B6-F8-KO hemophilia A mouse model by knocking out certain exons of the C57BL/6JGpt FVIII gene, which causes a frameshift mutation that results in FVIII protein deficit. This model can simulate the pathophysiology and main symptoms of hemophilia. It can also be used to evaluate the efficacy and safety of gene therapies and screening for other types of treatments for hemophilia A.


Application

  • Screening of hemophilia A therapeutics

  • Efficacy and safety evaluation of hemophilia A gene therapies

  • Pathogenesis study of hemophilia